KBY Biotech Indexv0.0.34
Search
← Pipeline|MRK-6781

MRK-6781

Approved
By Merck & Co
Source: Trial-derived·Trials: 2
Modality
Cell Therapy
MOA
RAS(ON)i
Target
TIGIT
Pathway
DDR
PsA
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Nov 2028
ApprovedCurrent
NCT04163715
1,763 pts·PsA
2017-06→2028-10·Terminated
NCT04202839
1,040 pts·PsA
2022-11→2028-11·Terminated
2,803 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2028-10-062.5y awayPh3 Readout· PsA
2028-11-042.6y awayPh3 Readout· PsA
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2028-10-06 · 2.5y away
PsA
Ph3 Readout
2028-11-04 · 2.6y away
PsA
Terminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT04163715ApprovedPsATerminated1763EASI-75
NCT04202839ApprovedPsATerminated1040ORR
Competitors (10)
DrugCompanyPhaseTargetMOA
ZanuderotideJohnson & JohnsonPhase 2/3TIGITGLP-1/GIP
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
PexamavacamtenDaiichi SankyoNDA/BLATIGITCD3xCD20
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
BNT-5232BioNTechNDA/BLATIGITPARPi
ALN-8757AlnylamPreclinicalTIGITCFTRmod
MiritinibNeurocrinePhase 3TIGITSTINGag
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
UTH-9370United TherapeuticsNDA/BLATIGITPARPi